Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608591 | 0.98 | PTGDR2 (0.52) | PTGDR2NPC1RAB9AALDH1A1TRIM24 | |
| Acetic Acid SCHEMBL27702447 | 0.91 | PTGDR2 (0.56) | PTGDR2NPC1RAB9AALDH1A1TRIM24 | |
| SCHEMBL4882683 | 0.84 | PTGDR2 (0.56) | PTGDR2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL6437932 | 0.83 | ESR2 (0.45) | PTGDR2NPC1RAB9AALDH1A1TRIM24 | |
| SCHEMBL6434946 | 0.82 | PDE10A (0.41) | PTGDR2NPC1RAB9AALDH1A1TRIM24 | |
| SCHEMBL6433294 | 0.81 | ESR2 (0.47) | PTGDR2NPC1RAB9AALDH1A1TRIM24 | |
| SCHEMBL31525817 | 0.81 | NPC1 (0.43) | NPC1RAB9AALDH1A1TRIM24TYR | |
| SCHEMBL6433205 | 0.80 | ESR2 (0.43) | PTGDR2NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL25705289 | 0.79 | MEN1 (0.48) | NPC1RAB9AALDH1A1TRIM24TYR | |
| SCHEMBL29871375 | 0.79 | ALDH1A1 (0.43) | RAB9AALDH1A1TYRCYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101184722-B | Novel resorcinol derivatives for skin | UNILEVER NV | 2011-06-22 | — | — | CN | claimed |
| US-7468464-B2 | Resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1861353-B1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2008-10-08 | — | — | EP | claimed |
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-06-05 | — | — | US | claimed |
| CN-101184722-A | Novel resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE (NL) | 2008-05-21 | — | — | CN | claimed |
| CN-101175711-A | Novel resorcinol derivatives | UNILEVER PLC (NL) | 2008-05-07 | — | — | CN | claimed |
| EP-1861353-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2007-12-05 | — | — | EP | claimed |
| EP-1858835-A1 | NOVEL RESORCINOL DERIVATIVES | UNILEVER PLC (GB) | 2007-11-28 | — | — | EP | claimed |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006097223-A1 | NOVEL RESORCINOL DERIVATIVES | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | claimed |
| WO-2006097224-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | claimed |
| US-20060210497-A1 | Novel resorcinol derivatives | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | claimed |
| CN-101184722-B | Novel resorcinol derivatives for skin | UNILEVER NV | 2011-06-22 | — | — | CN | disclosed |
| US-7468464-B2 | Resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1861353-B1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2008-10-08 | — | — | EP | disclosed |
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006097224-A1 | NOVEL RESORCINOL DERIVATIVES FOR SKIN | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097223-A1 | NOVEL RESORCINOL DERIVATIVES | UNILEVER PLC (GB) | 2006-09-21 | — | — | WO | disclosed |
| US-20060210497-A1 | Novel resorcinol derivatives | UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131382-A1 | Novel Resorcinol Derivatives for Skin | NR1H2, CYP1B1, NR0B1 | PTGDR2 1677/4885NPC1 1184/4885RAB9A 3070/4885 |
| US-20060210498-A1 | Novel resorcinol derivatives for skin | NR1H2, CYP1B1, NR0B1 | PTGDR2 1677/4885NPC1 1184/4885RAB9A 3070/4885 |
| US-20060210497-A1 | Novel resorcinol derivatives | NR1H2, DEGS1, NR1H3 | PTGDR2 741/4885NPC1 697/4885RAB9A 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.